Tag: Dermatitis
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document recommending Rinvoq (upadacitinib), from US drugmaker AbbVie (NYSE: ABBV), as a treatment of moderate to severe atopic dermatitis (AD) for adults and young people aged 12 and over, if the disease has not responded to at least […]
A study of UK electronic health record data indicated patients with atopic dermatitis (AD) showed an increased risk of dementia compared with the general population. Patients with atopic dermatitis (AD) exhibited an increased risk of incident dementia compared with the general population, and worse AD severity was linked with greater risk. Study findings were published […]
Core outcome sets (COS), important outcomes that should be measured in clinical trials, are largely absent in atopic dermatitis (AD) research. This prevents the combining of evidence from systematic reviews of important therapeutic interventions for AD, leading to a lack of unbiased evidence to guide clinical practice. The international Harmonising Outcome Measures for Eczema (HOME), […]
Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks. Approximately 70% of individuals with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least a 75% improvement in overall disease severity in the ADhere trial at 16 weeks, Eli […]